Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.
about
Stavudine toxicity in adult longer-term ART patients in Blantyre, MalawiSuccess with antiretroviral treatment for children in Kigali, Rwanda: experience with health center/nurse-based care.Hematologic changes associated with Zidovudine following single-drug substitution from stavudine in a home-based AIDS care program in rural Uganda.Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity.Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South AfricaIncidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.Implementation of a validated peripheral neuropathy screening tool in patients receiving antiretroviral therapy in Mombasa, KenyaClinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d'Ivoire.Incident neuropathy in HIV-infected patients on HAARTAdverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literatureBringing antiretroviral therapy (ART) closer to the end-user through mobile clinics and home-based ART: systematic review shows more evidence on the effectiveness and cost effectiveness is needed.Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting.Prevalence of peripheral neuropathy and its associated demographic and health status characteristics, among people on antiretroviral therapy in Rwanda.cART prescription trends in a prospective HIV cohort in rural Tanzania from 2007 to 2011.Incidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph?Sex differences in the incidence of peripheral neuropathy among Kenyans initiating antiretroviral therapyPharmacovigilance for antiretroviral drugs in Africa: lessons from a study in Abidjan, Cote d'Ivoire.The impact of herbal drug use on adverse drug reaction profiles of patients on antiretroviral therapy in zimbabweThe Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.Adverse drug reactions of Highly Active Antiretroviral Therapy (HAART) in HIV infected patients at the General Hospital, Douala, Cameroon: a cross sectional study.HIV peripheral neuropathy progression: protection with glucose-lowering drugs?HIV-associated sensory neuropathy in HIV-1 infected patients at the Douala General Hospital in Cameroon: a cross-sectional study.Underreporting of side effects of standard first-line ART in the routine setting in Blantyre, MalawiIncreased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya.Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathyProjecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age.Poor immunological recovery among severely immunosuppressed antiretroviral therapy-naïve Ugandans.HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa.Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy.Apoptosis: a clinically useful measure of antiretroviral drug toxicity?Antiretroviral treatment changes in adults from Côte d'Ivoire: the roles of tuberculosis and pregnancy.Prevalent neuropathy in a cohort of HIV-infected Kenyan sex workers using antiretroviral drugs.Evaluation of antiretroviral therapy (ART) provision in an early cohort of patients initiating ART in GhanaHIV-associated sensory neuropathy: risk factors and genetics.Painful HIV-associated sensory neuropathy.Adoption of new HIV treatment guidelines and drug substitutions within first-line as a measure of quality of care in rural Lesotho: health centers and hospitals compared.Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis.Adverse Drug Reactions to Antiretroviral Therapy in HIV-Infected Patients at the Largest Public Hospital in Nicaragua.
P2860
Q28481581-38C5087B-6063-43AE-990A-2E514E1441A5Q33373510-432F8898-9D40-4D19-B45E-401D051B1C81Q33383604-A3BA89F7-6E37-48E2-BF6A-7E03B8C1917FQ33394513-495DF4E7-F956-400F-8C72-45E920B1A171Q33533366-B0AC9C1A-BDDD-495A-89B7-786223A5DFF9Q33615251-9AF32893-73D7-4A88-A2D2-F83AC3D61C1BQ34087372-C6C5324B-D54D-4AFB-BDF6-C0C06D223539Q34097961-1649CD17-F6DA-4F3A-9B9F-0AA4B4099356Q34100209-0CA0C8DF-C348-4213-8B8A-81AD97037E30Q34174009-1A60C92C-A0C2-4B3E-BE5C-DDD877A6CF0AQ34444338-DF773B98-95F2-4005-B31B-DD2BBE936444Q34680326-AEA3D5F5-8FC8-4349-9351-22141B9FEBA8Q34732899-BFA68C65-F287-4608-BC34-7A145F1A68ACQ34973371-1C285850-7830-4100-981C-4AB3A1F8EE72Q35060210-8A1697C0-6325-4033-AC1E-8CC4E702F818Q35098097-F4F7A864-5189-485C-884E-BA6B5415E043Q35146943-095FC29F-CF7C-4F23-81E4-06259BA7ED35Q35164547-B567AC37-4F30-4491-B703-73FD874ADA8CQ35582624-FC94485E-A883-4E59-9239-4B3BACC65F2BQ35855545-1FC37301-E073-4C95-96DF-D9D02DF40036Q35930384-28D4C6AF-E676-4471-91C5-D2FFDAD0949BQ36325668-F331DEB2-411A-41E3-9631-FD4870AFA3D3Q36361767-E6759A05-945F-4562-86A6-4BDA903D76EAQ36478702-4D11A68A-2AAF-4821-A5C1-AD63ADBD7FF5Q36657527-B5A63C78-6464-4C68-8FA0-9062E249DF10Q37053758-95A70AFE-DCF4-42C4-9F2E-8B921761EE21Q37251569-26FB1A10-6335-4F38-A58B-6F06FF732CB0Q37326983-AC153425-09D9-4158-9392-F965F235FED2Q37378374-C3734ACE-2554-4C85-ABB5-E075EF7B79C2Q37419984-56AE9C54-B414-44EA-8C0F-72CC2619AEDEQ37453634-E370CE01-441C-47F8-80E6-6E803E9C8E4CQ37604387-ABF20673-206F-4167-BFFD-1181C5C09BD2Q37605850-FC4F9726-C3D4-4C06-A904-5971CB8E1078Q37608857-3BAF75F3-7541-497E-9159-C71C67EC93FEQ37721892-11E6221E-4200-451B-93E0-88C9FF4D53C1Q37988382-00C19F7F-C0EC-4E44-A6DF-EA39913E92F2Q38197249-FF3D9C70-D23A-4680-B256-F4F8340D3DFAQ39155410-92C37280-CE73-453B-B435-5A2985058898Q39553824-CFB6462A-2CA4-4FE1-8AFC-9A26C9D7CD52Q42210256-FB505062-B6C7-4787-9ABA-109C67D3C811
P2860
Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Clinical toxicity of highly ac ...... care program in rural Uganda.
@en
type
label
Clinical toxicity of highly ac ...... care program in rural Uganda.
@en
prefLabel
Clinical toxicity of highly ac ...... care program in rural Uganda.
@en
P2093
P1476
Clinical toxicity of highly ac ...... care program in rural Uganda.
@en
P2093
Cheryl A Liechty
Fatu Forna
Fred Asiimwe
John T Brooks
Jonathan Mermin
Paul J Weidle
Peter Solberg
Prosper Behumbiize
Willy Were
P304
P356
10.1097/QAI.0B013E318033FFA1
P407
P577
2007-04-01T00:00:00Z